<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/A97A8EC9-C79E-4701-BC21-6F259E0C8AE9"><gtr:id>A97A8EC9-C79E-4701-BC21-6F259E0C8AE9</gtr:id><gtr:name>Oslo University Hospital</gtr:name><gtr:address><gtr:line1>Ullevaal</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Medicine</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A97A8EC9-C79E-4701-BC21-6F259E0C8AE9"><gtr:id>A97A8EC9-C79E-4701-BC21-6F259E0C8AE9</gtr:id><gtr:name>Oslo University Hospital</gtr:name><gtr:address><gtr:line1>Ullevaal</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/11F43B87-CDF8-4F32-BABA-C9C646AE7C09"><gtr:id>11F43B87-CDF8-4F32-BABA-C9C646AE7C09</gtr:id><gtr:firstName>Gareth</gtr:firstName><gtr:otherNames>Haydn</gtr:otherNames><gtr:surname>Williams</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/6E2D22A7-2683-4976-970F-324735CB6317"><gtr:id>6E2D22A7-2683-4976-970F-324735CB6317</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:otherNames>Paul</gtr:otherNames><gtr:surname>Pereira</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/D0AC1EE7-2C16-4A9A-9376-E3FB5C5963AB"><gtr:id>D0AC1EE7-2C16-4A9A-9376-E3FB5C5963AB</gtr:id><gtr:firstName>Maesha</gtr:firstName><gtr:surname>Deheragoda</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/CAA2A1F1-85C2-4DF1-9CEF-A3433302360C"><gtr:id>CAA2A1F1-85C2-4DF1-9CEF-A3433302360C</gtr:id><gtr:firstName>Kai</gtr:firstName><gtr:surname>Stoeber</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0801588"><gtr:id>BC7F143C-FB3E-45EA-B586-87C1A5F648B8</gtr:id><gtr:title>Diagnosis of pancreaticobiliary malignancy by detection of minichromosome maintenance proteins in cytological specimens</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801588</gtr:grantReference><gtr:abstractText>The diagnosis of pancreatic and bile duct cancer at an early stage of disease remains difficult and there are no established tests to screen patients at high-risk of developing these cancers such as those with chronic pancreatitis (20x increased risk) and primary sclerosing cholangitis (160x increased risk). Blood tests and scans are not usually accurate enough to confirm the presence of cancer so cells are usually obtained from the lining of a narrowed bile duct with a brush (brush cytology) to look for cancer under the microscope. Brush cytology however only detects cancer in 20-50% of cases which means that patients often have to undergo additional invasive procedures, leading to potential complications and delays in diagnosis. Better diagnostic tests are clearly needed. 
 The aim of this study is to test new potential markers called minichromosome maintenance proteins (mcm 2-7) which may improve the early detection of precancerous changes and cancers involving the bile duct, and thus enhance the longevity and quality of life of patients living with pancreatic and bile duct cancer. These proteins are necessary for DNA replication which is essential for all cancer cells to multiply and grow. We have shown that the levels of these proteins are increased in a wide variety of early and advanced cancers in comparison to benign tissues, and can be used as accurate diagnostic tests for cervical, oesophageal and bladder cancer. 
 We have recently completed a study of 102 patients which showed that Mcm 5 protein when detected in bile is more than three times better than brush cytology at detecting pancreatic and biliary tract cancer, with up to 80% of cancers correctly diagnosed. The accuracy if this test depends in part on how many cells there are available to test. Brush cytology contains many more cells than bile and we now have exciting early results indicating that when Mcm 5 is detected in brush cytology specimens, close to 100% of cancers may be detected. We therefore plan to confirm these results by studying this marker as part of a large multicentre study, including patients at high risk of developing pancreatic and bile duct cancer.</gtr:abstractText><gtr:technicalSummary>The diagnosis of pancreatic and biliary tract cancer at an early stage of disease remains difficult and there are currently no established screening tests available, even in the high-risk groups of chronic pancreatitis (~20-fold increased risk of pancreatic cancer) and primary sclerosing cholangitis (~160-fold increased risk of biliary tract cancer). Biliary brush cytology is the standard method of sampling a biliary stricture but has a low sensitivity (20-50%) for the detection of malignancy. We have previously shown that minichromosome maintenance (MCM) replication proteins (Mcm2-7) are markers of dysplasia and have utilised these novel biomarkers of growth for the diagnosis of cervical and bladder cancer (Stoeber et al. Lancet 1999; Stoeber et al. JNCI 2002). 

Following on from these data in other solid organ tumours, we reported in a proof of principle prospective, blinded, single-centre study of 102 patients that Mcm5 levels in bile, detected by a two site time resolved immunofluorometric test with europium as a label, were significantly more sensitive (66% vs. 20%, p=0.004) than brush cytology for the detection of malignancy, with a comparable positive predictive value (97% vs. 100%, p=ns) (Ayaru et al. Br J Cancer 2008). In the same study, we also showed that Mcm 2 and 5 proteins detected in biopsy specimens are dysregulated in pancreaticobiliary malignancy. The percentage of nuclei positive for Mcm2 was higher in malignant tissue (median 76.5%, range 42-92%) than in benign tissue (median 5%, range 0-33%; p 0.0005), with similar results for Mcm5.

The sensitivity of the Mcm 5 test depends in part on the cellularity of bile, which can be acellular in up to 30% of samples, so that the sensitivity of bile aspirate Mcm5 cannot be expected to reach 100%. In contrast, the cellularity of brush cytology is much greater than bile aspirates. In a preliminary study of 20 patients with indeterminate biliary strictures, the Mcm 5 assay, when applied to biliary brush cytology specimens (n=20), had a sensitivity of 100% and an accuracy of 89% for the detection of malignancy (Ayaru et al, unpublished). We aim to extend these exciting preliminary data in a much larger group of patients with suspected pancreaticobiliary malignancy as part of a multicentre study, and to determine if the level of Mcm5 detected in brush cytology and bile specimens can distinguish accurately between the diagnostically challenging subgroups of: a) chronic pancreatitis and pancreatic cancer, and b) primary sclerosing cholangitis and biliary tract cancer.</gtr:technicalSummary><gtr:fund><gtr:end>2011-05-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-12-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>330873</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oslo University Hospital</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:department>Gastroenterology and Hepatology</gtr:department><gtr:description>International PSC Study Group</gtr:description><gtr:id>E4EC9397-3038-40F3-8612-D2F7F15D9297</gtr:id><gtr:impact>Nil</gtr:impact><gtr:partnerContribution>Plans for sharing of biological samples for ongoing studies</gtr:partnerContribution><gtr:piContribution>I chair the Cholangiocarcinoma working group within this international collaboration, which meets at least annually</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Pancreatic Cancer UK</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3E924F80-8F80-4D28-A954-5ABA03FBDADC</gtr:id><gtr:impact>Various presentations to members of Pancreatic Cancer UK, patients and the public about our research in cancer biomarker development.

Plans for ongoing links between UCL and PCUK to improve outcome in pancreatic cancer</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011,2012,2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR UCL/UCLH BRC BTC biomarkers Project grant</gtr:description><gtr:end>2016-07-02</gtr:end><gtr:fundingOrg>National Institute for Health Research (NIHR)</gtr:fundingOrg><gtr:id>99DE4270-46F1-44D4-9176-587B82739788</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>167608</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PCRF M2PK Project Grant</gtr:description><gtr:fundingOrg>Pancreatic Cancer Research Fund</gtr:fundingOrg><gtr:id>1F45C602-1C25-4442-9BD7-DF7DC78C1397</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>38000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>National Institute for Health Research (NIHR)</gtr:department><gtr:description>NIHR Flexibility and Sustainability Fund</gtr:description><gtr:fundingOrg>University College London Hospitals Charity (UCLH)</gtr:fundingOrg><gtr:id>7DF13B8B-2E29-4DCC-A448-C49CCF8B0B2B</gtr:id><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>140210</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PCUK CDC7 Project Grant</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Pancreatic Cancer UK</gtr:fundingOrg><gtr:id>9D6CB3D3-DF3B-4882-BEEF-C15BC82C2215</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR/BRC</gtr:department><gtr:description>Diagnostic markers for biliary tract cancer</gtr:description><gtr:end>2016-10-02</gtr:end><gtr:fundingOrg>National Institute for Health Research (NIHR)</gtr:fundingOrg><gtr:id>7F96859E-D3C8-41E4-9638-81CF6DF0A452</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>20618</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK PhD Research Bursary</gtr:description><gtr:fundingOrg>Cancer Research UK (CRUK)</gtr:fundingOrg><gtr:id>65CCEEBB-9851-4B03-816F-27812C4F60C4</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>National guidelines on cholangiocarcinoma (Gut 2012)</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C6CD65F4-8F06-48E4-B6C6-91F3B66FECCC</gtr:id><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>All Party Parliamentary Group on Pancreatic Cancer</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8BF9C728-B6DB-4483-B28C-D5220905EEBB</gtr:id><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>UK Multicentre collection of biological samples for the purposes of the study. Now ethically approved as TRANSBIL (TRANSlational research in BILiary tract cancer) and local SSIs being set up</gtr:description><gtr:id>A8543F12-0A15-4694-BC2F-B79CF56733BC</gtr:id><gtr:impact>Has been developed into a commercial assay in discussion with Cancer Research Technology</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>TRANSBIL</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DF1F48CD-147A-4CBA-8BFB-9474EB0A3B83"><gtr:id>DF1F48CD-147A-4CBA-8BFB-9474EB0A3B83</gtr:id><gtr:title>Imaging tumor variation in response to photodynamic therapy in pancreatic cancer xenograft models.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b71d3f2ef23925e4b86ec77a24e7aa5b"><gtr:id>b71d3f2ef23925e4b86ec77a24e7aa5b</gtr:id><gtr:otherNames>Samkoe KS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2D892BB3-AA2D-4A3D-B7A0-3AFA7641FB10"><gtr:id>2D892BB3-AA2D-4A3D-B7A0-3AFA7641FB10</gtr:id><gtr:title>Identification of potential serum peptide biomarkers of biliary tract cancer using MALDI MS profiling.</gtr:title><gtr:parentPublicationTitle>BMC clinical pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0a540299faef809d7c0c8bd9442ac64a"><gtr:id>0a540299faef809d7c0c8bd9442ac64a</gtr:id><gtr:otherNames>Sandanayake NS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1472-6890</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9C6378A1-63AF-459D-9002-955E802C8493"><gtr:id>9C6378A1-63AF-459D-9002-955E802C8493</gtr:id><gtr:title>The use of immunoglobulin g4 immunostaining in diagnosing pancreatic and extrapancreatic involvement in autoimmune pancreatitis.</gtr:title><gtr:parentPublicationTitle>Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5b2d420d82adc2b2dbf581f9a82ff8d8"><gtr:id>5b2d420d82adc2b2dbf581f9a82ff8d8</gtr:id><gtr:otherNames>Deheragoda MG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1542-3565</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C2A59E6D-BB7E-449F-8811-E834AD0DE6E3"><gtr:id>C2A59E6D-BB7E-449F-8811-E834AD0DE6E3</gtr:id><gtr:title>Systematic review: endoscopic and imaging-based techniques in the assessment of portal haemodynamics and the risk of variceal bleeding.</gtr:title><gtr:parentPublicationTitle>Alimentary pharmacology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/91a1edefbff02b8ff01041ddca36303d"><gtr:id>91a1edefbff02b8ff01041ddca36303d</gtr:id><gtr:otherNames>Sgouros SN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0269-2813</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/50BF2ED7-E4CF-4513-9C7E-B31ACE014BF5"><gtr:id>50BF2ED7-E4CF-4513-9C7E-B31ACE014BF5</gtr:id><gtr:title>Photodynamic therapy of malignant biliary strictures using meso-tetrahydroxyphenylchlorin.</gtr:title><gtr:parentPublicationTitle>European journal of gastroenterology &amp; hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/55b13ce447cbc1f555459191f079c45b"><gtr:id>55b13ce447cbc1f555459191f079c45b</gtr:id><gtr:otherNames>Pereira SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0954-691X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2F58FAE2-8C04-40AF-B1D9-B770B99B4700"><gtr:id>2F58FAE2-8C04-40AF-B1D9-B770B99B4700</gtr:id><gtr:title>Photodynamic therapy using verteporfin photosensitization in the pancreas and surrounding tissues in the Syrian golden hamster.</gtr:title><gtr:parentPublicationTitle>Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/42d7a2b458aceeb31c2c30e07841af3c"><gtr:id>42d7a2b458aceeb31c2c30e07841af3c</gtr:id><gtr:otherNames>Ayaru L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1424-3903</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FB2320D1-F8A8-4832-9F30-11CB8674A66E"><gtr:id>FB2320D1-F8A8-4832-9F30-11CB8674A66E</gtr:id><gtr:title>Re: Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on incidence of intra- and extrahepatic cholangiocarcinoma in the United States.</gtr:title><gtr:parentPublicationTitle>Journal of the National Cancer Institute</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2bd3e3eb934736ae31e829fade90e037"><gtr:id>2bd3e3eb934736ae31e829fade90e037</gtr:id><gtr:otherNames>Matull WR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0027-8874</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7FEF5BF2-5CBA-4FFF-B812-84932C3B0048"><gtr:id>7FEF5BF2-5CBA-4FFF-B812-84932C3B0048</gtr:id><gtr:title>Cholangiocarcinoma: improving biliary drainage with PDT.</gtr:title><gtr:parentPublicationTitle>Photodiagnosis and photodynamic therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2ae2195e63b486814855772fed3eea6b"><gtr:id>2ae2195e63b486814855772fed3eea6b</gtr:id><gtr:otherNames>Chapman MH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1572-1000</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C4E3586D-1040-469C-8459-5E56039D8A96"><gtr:id>C4E3586D-1040-469C-8459-5E56039D8A96</gtr:id><gtr:title>Diagnosis of pancreaticobiliary malignancy by detection of minichromosome maintenance protein 5 in biliary brush cytology.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1f937546eb8b83a4e14e74d583479d70"><gtr:id>1f937546eb8b83a4e14e74d583479d70</gtr:id><gtr:otherNames>Keane MG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3C0EE828-F2E0-4941-B0FD-220B97A644F3"><gtr:id>3C0EE828-F2E0-4941-B0FD-220B97A644F3</gtr:id><gtr:title>MUC4 and MUC5AC are highly specific tumour-associated mucins in biliary tract cancer.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2bd3e3eb934736ae31e829fade90e037"><gtr:id>2bd3e3eb934736ae31e829fade90e037</gtr:id><gtr:otherNames>Matull WR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8F07C5EB-D4C6-4773-B4D3-354F3B65265F"><gtr:id>8F07C5EB-D4C6-4773-B4D3-354F3B65265F</gtr:id><gtr:title>Pyruvate kinase M2 is a novel diagnostic marker and predicts tumor progression in human biliary tract cancer.</gtr:title><gtr:parentPublicationTitle>Cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b057b86f073d2014a3c88cbeeaa183ef"><gtr:id>b057b86f073d2014a3c88cbeeaa183ef</gtr:id><gtr:otherNames>Dhar DK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0008-543X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4776826D-A758-45FD-8362-781B9BACDAAD"><gtr:id>4776826D-A758-45FD-8362-781B9BACDAAD</gtr:id><gtr:title>Cdc7 is a potent anti-cancer target in pancreatic cancer due to abrogation of the DNA origin activation checkpoint.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/27e30c1e6d081c1532706adeec54bc38"><gtr:id>27e30c1e6d081c1532706adeec54bc38</gtr:id><gtr:otherNames>Huggett MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F5D746D3-9FED-468E-9717-1D266A99589B"><gtr:id>F5D746D3-9FED-468E-9717-1D266A99589B</gtr:id><gtr:title>Complications and diagnostic difficulties arising from biliary self-expanding metal stent insertion before definitive histological diagnosis.</gtr:title><gtr:parentPublicationTitle>Journal of gastroenterology and hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/42d7a2b458aceeb31c2c30e07841af3c"><gtr:id>42d7a2b458aceeb31c2c30e07841af3c</gtr:id><gtr:otherNames>Ayaru L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0815-9319</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EC3097E4-9787-422F-BCBB-AA9B500090EA"><gtr:id>EC3097E4-9787-422F-BCBB-AA9B500090EA</gtr:id><gtr:title>EUS-guided tissue sampling: comparison of &amp;quot;dual sampling&amp;quot; (Trucut biopsy plus FNA) with &amp;quot;sequential sampling&amp;quot; (Trucut biopsy and then FNA as required).</gtr:title><gtr:parentPublicationTitle>Endoscopy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f04ed898fa84858a60e385a8099f4e26"><gtr:id>f04ed898fa84858a60e385a8099f4e26</gtr:id><gtr:otherNames>Aithal GP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0013-726X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AB98CED6-3ED9-4398-83FF-1C189478F99C"><gtr:id>AB98CED6-3ED9-4398-83FF-1C189478F99C</gtr:id><gtr:title>Diagnosis of pancreaticobiliary malignancy by detection of minichromosome maintenance protein 5 in bile aspirates.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/42d7a2b458aceeb31c2c30e07841af3c"><gtr:id>42d7a2b458aceeb31c2c30e07841af3c</gtr:id><gtr:otherNames>Ayaru L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0B12035C-7C70-4EF7-8D02-BC958D06A8E8"><gtr:id>0B12035C-7C70-4EF7-8D02-BC958D06A8E8</gtr:id><gtr:title>Autoimmune pancreatitis/IgG4-associated cholangitis and primary sclerosing cholangitis--overlapping or separate diseases?</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6be22181e65319312bcaf4fe79256e1f"><gtr:id>6be22181e65319312bcaf4fe79256e1f</gtr:id><gtr:otherNames>Webster GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801588</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>